The carcinomas with BAP1 or MTAP loss included one adenocarcinoma with <80% EZH2 staining and negative CD117 staining, such that the addition of BAP1 and MTAP to a panel of EZH2 (≥80% threshold) and CD117 slightly increased the sensitivity for carcinoma from 92% to 95%. The gene discussed is EZH2; the disease is adenocarcinoma.